Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Fabino Enterprises Ltd. shows poor financial metrics relative to its peers in the Pharmaceuticals & Drugs industry, indicating a lack of growth and profitability. Among its peers, Sun Pharmaceutical Industries Ltd. and Cipla Ltd. demonstrate robust profitability and growth metrics, marking them as industry leaders. Conversely, Fabino appears financially weak with no revenue and losses in cash flow, making it a significant underperformer in the sector.
Strong revenue growth (8.42% YoY), high profitability (ROE of 16.13%), and solid EPS growth.
Consistent revenue growth (13.28% YoY) and attractive valuation metrics (low PE of 23.73 and PEG of 0.35).